Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125209622 | 12520962 | 2 | F | 201412 | 20160714 | 20160701 | 20160714 | EXP | JP-GLAXOSMITHKLINE-JP2016JPN091307 | GLAXOSMITHKLINE | SHIGA Y, KANAYA Y, KONO R, TAKESHIMA S, SHIMOE Y, KURIYAMA M. DEMENTIA WITH LEVY BODIES PRESENTING MARKED TONGUE PROTRUSION AND BITE DUE TO LINGUAL DYSTONIA: A CASE REPORT. CLINICAL NEUROLOGY. 2016;56:418-423 | 53.00 | YR | F | Y | 0.00000 | 20160714 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125209622 | 12520962 | 1 | PS | REQUIP | ROPINIROLE HYDROCHLORIDE | 1 | Oral | 1 MG, 1D | Y | 22008 | 1 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 125209622 | 12520962 | 2 | SS | REQUIP | ROPINIROLE HYDROCHLORIDE | 1 | Oral | 6 MG, 1D | Y | 22008 | 6 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 125209622 | 12520962 | 3 | SS | L DOPA | LEVODOPA | 1 | Oral | UNK UNK, 1D | Y | N | 0 | ||||||||
| 125209622 | 12520962 | 4 | C | BIPERIDEN HYDROCHLORIDE | BIPERIDEN HYDROCHLORIDE | 1 | 3 MG, 1D | 0 | 3 | MG | QD | ||||||||
| 125209622 | 12520962 | 5 | C | YOKUKANSAN | HERBALS | 1 | UNK | 0 | |||||||||||
| 125209622 | 12520962 | 6 | C | ROTIGOTINE | ROTIGOTINE | 1 | 0 | ||||||||||||
| 125209622 | 12520962 | 7 | C | CLONAZEPAM. | CLONAZEPAM | 1 | 1.5 MG, 1D | 0 | 1.5 | MG | QD | ||||||||
| 125209622 | 12520962 | 8 | C | BROTIZOLAM | BROTIZOLAM | 1 | 0.25 MG, 1D | 0 | .25 | MG | QD | ||||||||
| 125209622 | 12520962 | 9 | C | UNKNOWN DRUG | UNSPECIFIED INGREDIENT | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125209622 | 12520962 | 1 | Parkinsonism |
| 125209622 | 12520962 | 3 | Parkinsonism |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125209622 | 12520962 | LT |
| 125209622 | 12520962 | HO |
| 125209622 | 12520962 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125209622 | 12520962 | Altered state of consciousness | |
| 125209622 | 12520962 | Blood creatine phosphokinase increased | |
| 125209622 | 12520962 | Drug hypersensitivity | |
| 125209622 | 12520962 | Dyskinesia | |
| 125209622 | 12520962 | Fibrin D dimer increased | |
| 125209622 | 12520962 | Hypotonia | |
| 125209622 | 12520962 | Laryngeal dyspnoea | |
| 125209622 | 12520962 | Miosis | |
| 125209622 | 12520962 | Mood swings | |
| 125209622 | 12520962 | Muscular weakness | |
| 125209622 | 12520962 | Neuroleptic malignant syndrome | |
| 125209622 | 12520962 | Oedema peripheral | |
| 125209622 | 12520962 | Oromandibular dystonia | |
| 125209622 | 12520962 | Protrusion tongue | |
| 125209622 | 12520962 | Tongue biting | |
| 125209622 | 12520962 | Tongue discolouration | |
| 125209622 | 12520962 | Tongue haemorrhage | |
| 125209622 | 12520962 | Tongue movement disturbance | |
| 125209622 | 12520962 | Unresponsive to stimuli | |
| 125209622 | 12520962 | Vascular insufficiency | |
| 125209622 | 12520962 | Vocal cord disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125209622 | 12520962 | 1 | 201411 | 201411 | 0 | |
| 125209622 | 12520962 | 2 | 201411 | 2015 | 0 | |
| 125209622 | 12520962 | 3 | 201309 | 2015 | 0 | |
| 125209622 | 12520962 | 4 | 201310 | 2015 | 0 |